The first production floor is dedicated to the manufacture of sterile products, employing advanced technologies that ensure aseptic conditions critical to product integrity. The second floor is focused on solid products, such as tablets and capsules, designed to accommodate large-scale production in compliance with Good Manufacturing Practices (GMP). The third floor is currently under design and will be dedicated to manufacturing sterile Penem group products, expanding HPL’s portfolio of high-quality antibiotics.

This facility features an independent and dedicated material loading/unloading system, along with advanced HVAC systems and a comprehensive water distribution system, all designed to create optimal production conditions. The facility is also equipped with strategic firefighting systems to mitigate potential hazards, reflecting HPL’s strong commitment to operational safety. Additionally, a nearby utility building provides all necessary support for production activities, ensuring efficiency throughout the manufacturing process.

The Cephalosporin Unit adheres to Good Manufacturing Practices (GMP) approved by the Directorate General of Drug Administration (DGDA), Ministry of Health & Family Welfare, Bangladesh. HPL is also actively working towards obtaining GMP certifications from the Therapeutic Goods Administration (TGA), Australia, and ANVISA (National Health Surveillance Agency), Brazil, to further broaden its global reach. 

The facility is specialized in manufacturing a variety of cephalosporin products, including tablets, capsules, powder for suspension, and powder for injection. With the latest pharmaceutical manufacturing technologies and a team of highly skilled professionals, the Cephalosporin Unit maintains rigorous quality controls throughout production, ensuring compliance with international standards.

Since its inception, the Cephalosporin Unit has marked several milestones, starting with the production of powder for injection in January 2020, followed by the production of tablets, capsules, and powder for suspension in July 2021. With a strong focus on innovation and quality, HPL’s Cephalosporin Unit continues to play a significant role in providing effective antibiotic therapies to address global healthcare needs.